NCT05620771 2025-10-20
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Suspended
Clinical Trials
13 trialsNCT07070076 2025-08-27
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
First Affiliated Hospital of Jinan University
Phase NA Recruiting
NCT01349075 2025-04-29
TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
Thomas Jefferson University
Completed
NCT04108481 2025-03-28
iRE-C
University of Iowa
Phase 1 Terminated
NCT03889093 2025-03-24
Radioembolization of Primary and Secondary Liver Malignancies and The Effect On The Immune System
University of Minnesota
Phase NA Terminated
NCT05655949 2025-03-10
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
Phase 2 Recruiting
NCT06725121 2024-12-16
MacroTrans
University Health Network, Toronto
Phase 1/2 Recruiting
NCT06375915 2024-05-24
PM-CARE
IRCCS San Raffaele
Phase 2 Recruiting
NCT03300401 2019-05-16
Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization
University of Southern California
Phase NA Withdrawn
NCT02787954 2018-10-18
Liver
The University of Texas Health Science Center, Houston
Terminated
NCT00846131 2016-09-15
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
Northwestern University
Phase 1 Completed
NCT02724436 2016-03-31
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase NA Completed
NCT00766220 2013-01-03
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
M.D. Anderson Cancer Center
Phase 2 Withdrawn